HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
NBIX
Neurocrine Biosciences, Inc.
NBIX's fundamentals are strong and it looks cheap: trading at 25x earnings, below its usual 45x. Analysts expect strong earnings growth, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
NBIX Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
NBIX's revenue, profitability, cash flow and balance sheet are all currently strong.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
NBIX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 19x | $169 | — |
| Cheap | 25x | $169 | -0.3% |
| Current | 25x | $169 | — |
| Fair | 44x | $297 | +75% |
| Expensive | 145x | $981 | +479% |
Historical ranges are pointers, not guarantees.
NBIX's PE is in its cheap range at 25x. If earnings grow as analysts expect, today's price would be 19x next year's earnings.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
NBIX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Improving | |
| Limited | |
| Low |
NBIX has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
NBIX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.06 | +34% |
| Q3 2026 | $6.75 | +61% |
| Q2 2026 | $6.83 | +102% |
| Q1 2026 | $6.50 | +120% |
| Q4 2025 | $4.67 | +42% |
| Q3 2025 | $4.18 | +11% |
| Q2 2025 | $3.38 | +0.6% |
| Q1 2025 | $2.95 | -20% |
| Q4 2024 | $3.29 | +33% |
NBIX has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over NBIX on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
NBIX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.1B | +41% |
| Q2 2026 | $959M | +39% |
| Q1 2026 | $814.5M | +42% |
| Q4 2025 | $805.5M | +28% |
| Q3 2025 | $794.9M | +28% |
| Q2 2025 | $687.5M | +16% |
| Q1 2025 | $572.6M | +11% |
| Q4 2024 | $627.7M | +22% |
NBIX's revenue has grown year over year for 21 quarters in a row: $1.1B last quarter, up 41% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -0.6 points |
| Q2 2026 | 16% | -5.4 points |
| Q1 2026 | 24% | +20 points |
| Q4 2025 | 26% | +3.6 points |
| Q3 2025 | 30% | +0.5 points |
| Q2 2025 | 21% | -3.5 points |
| Q1 2025 | 4.1% | -15 points |
| Q4 2024 | 23% | -6.6 points |
NBIX has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
NBIX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $383.6M | +79% |
| Q2 2026 | $128.6M | +44% |
| Q1 2026 | $136.7M | +153% |
| Q4 2025 | $390.8M | +66% |
| Q3 2025 | $214.3M | +43% |
| Q2 2025 | $89.5M | +69% |
| Q1 2025 | $54.1M | -55% |
| Q4 2024 | $235.2M | +99% |
NBIX generated $1B in free cash flow over the past year, up 75% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over NBIX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
NBIX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1% | +1M shares |
| 1 year | +2.6% | +2.7M shares |
| 3 years | +4.1% | +4.1M shares |
| 5 years | +7.7% | +7.5M shares |
| Available history | +8.2% | +8M shares |
NBIX has 105M diluted shares, up 2.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $92.1M |
| Q2 2026 | $12M |
| Q1 2026 | $54M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $17.7M |
| Q1 2025 | $150M |
NBIX spent $158M buying back its own shares over the past year.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
NBIX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.7x | Net Cash |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | -1.1x | Net Cash |
| Q3 2025 | -0.6x | Net Cash |
| Q2 2025 | -0.5x | Net Cash |
| Q1 2025 | -0.4x | Net Cash |
| Q4 2024 | -0.4x | Net Cash |
NBIX has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
NBIX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 61.7 | Neutral |
| Stochastic | 65.8 | Neutral |
NBIX's weekly RSI is 62 (neutral) and its Stochastic is 66 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
NBIX PE vs Healthcare Sector
| Metric | NBIX | Sector median | Relative |
|---|---|---|---|
| PE | 25x | 26x | 2.9% below |
| PE % | 17 | 29 | 12 pts below |
NBIX is trading at 25x earnings, in line with the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
NBIX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $147.8 | 15% above |
| 20 week MA | $156.4 | 8.3% above |
| 50 week MA | $147.5 | 15% above |
| 100 week MA | $138.4 | 22% above |
| 200 week MA | $128.9 | 31% above |
NBIX has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
NBIX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $108.4 | $97.7 | -9.9% |
| 2021 | $97.7 | $85.1 | -13% |
| 2022 | $85.1 | $120.3 | +41% |
| 2023 | $120.3 | $131.8 | +9.5% |
| 2024 | $131.8 | $139.4 | +5.8% |
| 2025 | $139.4 | $145.3 | +4.2% |
| 2026 YTD | $145.3 | $169.4 | +17% |
NBIX has the edge over HIMS on returns for 2026, with the stronger performance.